1. Lockheed martin deal production will start from FY24
2. Substantial breakthrough in feed additive business and focus to expand business in north and central America geographies
3. Entering in geographies of Ecuador for aquatic market
4. 4-5 new products to be introduced in new feed additives business segment with revenue potential of ₹250-300 Cr in 3-4 years
5. Catechol is having limited induce and hydroquinone is facing challenges in demand and expected to continue further
6. Price pass on is partially done in hydroquinone, rest of the pass on will be done in upcoming qtrs
7. For CFS North America, revenue is expected to stay at break even until FY23
8. Evaluating options to manufacture MEHQ from anisole
9. 17-20% EBITDA margins sustainable post vanillin capex
10. Pricing is now done on a quarterly basis. 80% of business is direct consumer driven and rest 20% is distributor driven
CSF regional breakup
1. India- Revenues stood at ₹200Cr with growth of 22% YoY 2. Mexico- Revenues stood at ₹91.3Cr with growth of 29% YoY 3. Europe- Revenues stood at ₹87.4Cr with growth of 26% YoY 4. Brazil- Revenues stood at ₹22.1Cr with growth of 21% YoY
5. North America- Revenues stood at ₹13.4Cr with growth of 68% YoY
Capex
1. CAPEX program on track with Ethyl / Methyl Vanillin
at Dahej SEZ expected to achieve mechanical completion in March 2. 2022 and commercial production in June / July 2022 3. ₹30-40Cr capex for new business segments i.e. feed additives.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. Revenues for the quarter stood at ₹2376 Cr, with a robust growth of 100.1% YoY
2. Both the Pharmaceuticals & Specialty Chemicals segment outperformed during the quarter
3. Revenue expansion during the quarter includes cost escalations passed on to the customers due to substantial increase in raw material prices as well as fuel and logistics costs
4. Accrual of termination fees in respect of the long-term contract of ₹631 crores resulting in higher revenues. As a result, EBITDA includes ₹611 Crs during the quarter.
1. Revenues from operations stood at Rs. 396.6 crore in Q3FY22 as against Rs. 375.4 crore in Q3FY21, higher by 5.6%
2. EBITDA margins remained stable on a sequential basis at 15.8% translating to EBITDA of 63.8 crore
3. Gross margins in 9M FY22 stood at 41.4%
4. Q3 FY22 revenues growth was driven on the back of rebound in consumer demand led by discretionary items and new client wins.
5. While the domestic core fragrance segment delivered healthy performance, sales in Southeast Asia region continued to be affected by the Covid surge and is yet to recover
1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
2. EBITDA was at ₹1016 Cr (20% decline YoY) for the quarter. EBITDA margins for the quarter were 16.9%. PAT stood at ₹604.3 Cr (80% decline YoY).
3. Revenue from formulations was ₹4992 Cr (12% decline YoY).
4. Formulations contributed about 83% of total revenues. Revenue from the API business stood at ₹1010 Cr (48% growth YoY) and contributed about 17% of revenues.
1. Revenues are flat and profitability is down because of the high base effect.
2. Q3 and Q4 of FY21 were phenomenal quarters for the company because there was a major poultry disease outbreak which led to increased demand for vaccines.
3. They also have additional income every year from licensing fees which is not there in Q3 FY22.
4. They have been working on 3 vaccines - classical swine fever, lumpy skin disease and sheep pox vaccine. All these vaccines are in the final stages of quality testing and regulatory approval and they hope to launch them in Q1 FY23.